See more : Gunther Grant, Inc. (GNGR) Income Statement Analysis – Financial Results
Complete financial analysis of Samsung Biologics Co.,Ltd. (207940.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Samsung Biologics Co.,Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Archidply Industries Limited (ARCHIDPLY.BO) Income Statement Analysis – Financial Results
- Orient International Enterprise, Ltd. (600278.SS) Income Statement Analysis – Financial Results
- International Precious Minerals Group, Inc. (IPMG) Income Statement Analysis – Financial Results
- SNL Bearings Limited (SNL.BO) Income Statement Analysis – Financial Results
- Macarthur Minerals Limited (MIO.AX) Income Statement Analysis – Financial Results
Samsung Biologics Co.,Ltd. (207940.KS)
About Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,694.59B | 3,001.30B | 1,568.01B | 1,164.78B | 701.59B | 535.81B | 464.63B | 294.62B | 91.28B | 105.15B |
| Cost of Revenue | 1,900.08B | 1,532.85B | 841.56B | 748.70B | 509.58B | 390.65B | 332.83B | 268.09B | 114.78B | 124.87B |
| Gross Profit | 1,794.51B | 1,468.45B | 726.45B | 416.08B | 192.01B | 145.16B | 131.80B | 26.53B | -23.51B | -19.72B |
| Gross Profit Ratio | 48.57% | 48.93% | 46.33% | 35.72% | 27.37% | 27.09% | 28.37% | 9.01% | -25.75% | -18.75% |
| Research & Development | 81.59B | 45.88B | 75.96B | 5.11B | 48.51B | 0.00 | 0.00 | 0.00 | 0.00 | 186.74M |
| General & Administrative | 135.72B | 114.07B | 33.34B | 24.70B | 21.58B | 18.03B | 16.01B | 15.00B | 28.50B | 20.52B |
| Selling & Marketing | 167.81B | 95.42B | 69.67B | 33.06B | 34.78B | 24.96B | 11.51B | 11.90B | 66.67B | 20.79B |
| SG&A | 556.93B | 209.49B | 103.01B | 57.76B | 56.36B | 43.00B | 27.52B | 26.90B | 95.18B | 41.30B |
| Other Expenses | 0.00 | 229.45B | 86.13B | 60.42B | 43.91B | -6.94B | 758.69M | 1.18B | 2.43B | 58.82B |
| Operating Expenses | 638.52B | 484.82B | 189.14B | 123.29B | 100.27B | 89.48B | 65.82B | 56.96B | 180.14B | 99.82B |
| Cost & Expenses | 2,538.60B | 2,017.67B | 1,030.70B | 871.99B | 609.85B | 480.13B | 398.65B | 325.04B | 294.92B | 224.69B |
| Interest Income | 95.65B | 53.29B | 9.66B | 13.14B | 17.25B | 9.65B | 9.95B | 3.64B | 1.18B | 3.01B |
| Interest Expense | 81.60B | 64.06B | 14.71B | 16.09B | 25.61B | 15.84B | 5.68B | 19.25B | 2.65B | 2.47B |
| Depreciation & Amortization | 489.78B | 308.26B | 161.79B | 143.17B | 132.54B | 91.45B | 69.93B | 60.15B | 41.63B | 26.35B |
| EBITDA | 1,691.86B | 1,354.09B | 723.93B | 443.02B | 240.65B | 410.26B | -40.38B | -22.27B | 2,532.34B | -70.87B |
| EBITDA Ratio | 45.79% | 45.75% | 47.24% | 37.02% | 44.68% | 76.65% | 4.03% | -33.08% | 4,769.35% | -66.61% |
| Operating Income | 1,155.99B | 983.63B | 537.31B | 292.79B | 180.62B | 55.68B | 65.98B | -30.42B | -203.64B | -119.54B |
| Operating Income Ratio | 31.29% | 32.77% | 34.27% | 25.14% | 25.74% | 10.39% | 14.20% | -10.33% | -223.10% | -113.69% |
| Total Other Income/Expenses | -36.00B | 25.40B | 23.97B | -26.79B | 63.69B | 247.30B | -181.97B | -200.48B | 2,691.71B | 19.85B |
| Income Before Tax | 1,119.99B | 1,009.02B | 561.28B | 265.99B | 155.44B | 302.98B | -115.99B | -230.90B | 2,488.06B | -99.69B |
| Income Before Tax Ratio | 30.31% | 33.62% | 35.80% | 22.84% | 22.15% | 56.55% | -24.97% | -78.37% | 2,725.81% | -94.81% |
| Income Tax Expense | 262.30B | 210.97B | 167.69B | 25.02B | -47.47B | 78.87B | -19.02B | -54.08B | 583.12B | 19.37B |
| Net Income | 857.69B | 798.06B | 393.59B | 240.97B | 202.90B | 224.11B | -96.97B | -176.82B | 1,904.95B | -95.91B |
| Net Income Ratio | 23.21% | 26.59% | 25.10% | 20.69% | 28.92% | 41.83% | -20.87% | -60.02% | 2,086.97% | -91.21% |
| EPS | 12.05K | 11.44K | 5.89K | 3.60K | 3.03K | 3.35K | -1.45K | -3.08K | 38.42K | -5.56K |
| EPS Diluted | 12.05K | 11.43K | 5.89K | 3.60K | 3.03K | 3.35K | -1.45K | -3.08K | 38.42K | -5.56K |
| Weighted Avg Shares Out | 71.17M | 69.75M | 66.87M | 66.87M | 66.87M | 66.87M | 66.85M | 57.37M | 49.98M | 17.24M |
| Weighted Avg Shares Out (Dil) | 71.17M | 69.81M | 66.87M | 66.87M | 66.87M | 66.87M | 66.85M | 57.37M | 49.98M | 17.24M |
Source: https://incomestatements.info
Category: Stock Reports